Distinguished in Gallbladder Disease

Thorsten O. Goetze

Frankfurt Am Main, HE, DE 
Distinguished in Gallbladder Disease
Frankfurt Am Main, HE, DE 
OverviewLocationsClinical Research

Overview

Thorsten Goetze practices in Frankfurt Am Main, Germany. Mr. Goetze is rated as a Distinguished expert by MediFind in the treatment of Gallbladder Disease. His top areas of expertise are Gallbladder Disease, Gallbladder Cancer, Stomach Cancer, Gallbladder Removal, and Hepatectomy.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 15 articles and participated in 3 clinical trials in the study of Gallbladder Disease.

Gender
Male

Locations

Frankfurt Am Main, HE, Germany
Other Locations
Offenbach, HE 63071, Germany
Hessen, ST 63071, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 3
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Dostarlimab, Pembrolizumab, Chemotherapy
Study Phase: Phase 2
A Phase II Study of Immunotherapy With Durvalumab and Tremelimumab in Combination With Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer
A Phase II Study of Immunotherapy With Durvalumab and Tremelimumab in Combination With Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab, Capecitabine
Study Phase: Phase 2
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) A Multicenter, Prospective, Cohort Study To Assess The Genomic Profiles And Associated Therapy Decision In Gastrointestinal Cancer
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) A Multicenter, Prospective, Cohort Study To Assess The Genomic Profiles And Associated Therapy Decision In Gastrointestinal Cancer
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: March 20, 2025
Intervention Type: Drug
Study Drug: Trabectidin
Study Phase: Phase 4
A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients With Preserved Liver Function
A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients With Preserved Liver Function
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Drug
Study Drug: Cabozantinib Oral Tablet
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Enrollment Status: Completed
Publish Date: March 07, 2024
Intervention Type: Other
Comprehensive Genomic Profiling Combined With Real Life Data of The German-Registry of Incidental Gallbladder Carcinoma the CONGENIAL Analysis Sub-study of the GR
Comprehensive Genomic Profiling Combined With Real Life Data of The German-Registry of Incidental Gallbladder Carcinoma the CONGENIAL Analysis Sub-study of the GR
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2024
View 9 Less Clinical Trials

81 Total Publications

Response to the Letter to the Editor: Critical appraisal of the IKF-010 trial.
Response to the Letter to the Editor: Critical appraisal of the IKF-010 trial.
Journal: Clinical nutrition ESPEN
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Goetze's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile